Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand-Reference-Cited by-同舟云学术

Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand

Published:2013-03-05 Issue:4 Volume:88 Page:251-260
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol

Author:

Viprakasit Vip¹,Nuchprayoon Issarang²,Chuansumrit Ampaiwan³,Torcharus Kitti⁴,Pongtanakul Bunchoo¹,Laothamatas Jiraporn⁵,Srichairatanakool Somdet⁶,Pooliam Julaporn⁷,Supajitkasem Siriwat⁸,Suriyaphol Prapat⁸,Tanphaichitr Voravarn S.¹⁹,Tuchinda Soodsarkorn⁹

Affiliation:

1. Hematology/Oncology Division, Department of Pediatrics and Thalassemia Center; Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok Thailand

2. Department of Pediatrics; King Chulalongkorn Memorial Hospital, Chulalongkorn University; Bangkok Thailand

3. Department of Pediatrics; Ramathibodi Hospital, Mahidol University; Bangkok Thailand

4. Department of Pediatrics; Phramongkutklao College of Medicine; Bangkok Thailand

5. Department of Radiology; Ramathibodi Hospital, Mahidol University; Bangkok Thailand

6. Department of Biochemistry; Faculty of Medicine; Chiang Mai University; Chiang Mai, Bangkok Thailand

7. Clinical Epidemiology Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital; Mahidol University; Bangkok Thailand

8. Bioinformatics and Data Management for Research Unit; Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok Thailand

9. Thalassemia Foundation of Thailand (TFT); Bangkok Thailand

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23386/fullpdf

Reference59 articles.

1. Late effects of bone marrow transplantation for thalassemia;Piga;Ann N Y Acad Sci,1998

2. HLA-matched sibling bone marrow transplantation for beta-thalassemia major;Sabloff;Blood,2011

3. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens;Viprakasit;J Med Assoc Thai,2001

4. Survival and causes of death in thalassaemia major;Zurlo;Lancet,1989

5. Iron-chelating therapy and the treatment of thalassemia;Olivieri;Blood,1997

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs;International Journal of Molecular Sciences;2023-11-25

2. Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects;International Journal of Molecular Sciences;2023-03-04

3. Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients;Pharmacy Practice;2022-03-26

4. Characterisation of individual ferritin response in patients receiving chelation therapy;British Journal of Clinical Pharmacology;2022-03-26

5. The Long-Term Efficacy of Deferiprone in Thalassemia Patients With Iron Overload: Real-World Data from the Registry Database;Hemoglobin;2022-03-04